IL6 and colitis: Apigenin treatment inhibited colon damage, MPO activity, and the production of IL-1β, TNF-α, and IL-6 in DSS-induced colitis, as well as the NF-κB and STAT3 pathways in colitis-associated colon cancer tissues in mice [164].